EUCTR2004-002103-32-IE进行中（未招募）不适用
Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma, eligible for transplantation followed by randomised maintenance treatment with Rituximab - Coral
GELA-Recherche Clinique0 个研究点目标入组 400 人开始时间: 2004年8月16日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with CD20 positive diffuse large B-cell lymphoma.Disease must be histologically proven in case ofrelapse or partial response
- •Aged 18-65
- •Eligible for transplanatation
- •ECOG performance <=2
- •Previously treated with chemotherapy regimen containing anthracyclines with or without rituximab
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Burkitt, mantle-cell and T-cell lymphoma
- •CD20 negative diffuse large cell lymphoma
- •Not previouly treated with anthracycline-containing regimens
- •Prior transplantation
研究者
相似试验
进行中（未招募）
1 期
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AAdvanced relapsed ovarian cancerMedDRA version: 9.1 Level: LLT Classification code 10033130 Term: Ovarian cancer NOSEUCTR2004-005276-16-GBPharma Mar S.A.650
进行中（未招募）
不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AEUCTR2004-005276-16-BEPharma Mar S.A.650
进行中（未招募）
不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AAdvanced relapsed ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSEUCTR2004-005276-16-DEPharma Mar S.A.650
进行中（未招募）
不适用
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer. - N/AAdvanced relapsed ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033130Term: Ovarian cancer NOSEUCTR2004-005276-16-SEPharma Mar S.A.650
进行中（未招募）
1 期
An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS™ with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.Advanced relapsed ovarian cancerMedDRA version: 5.0Level: DTClassification code 10033130EUCTR2004-005276-16-ESPharma Mar S.A. Sociedad Unipersonal650